OncoMatch/Clinical Trials/NCT07042581
A Study of Revaree Plus in People With Breast Cancer
Is NCT07042581 recruiting? Yes, currently enrolling (May 2026). This Phase 4 trial studies Revaree Plus for breast cancer.
Treatment: Revaree Plus — The purpose of this study is to find out whether Revaree Plus is effective at improving vaginal health for people who are having symptoms of vaginal dryness during breast cancer treatment.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Tumor Agnostic
Biomarker criteria
Required: ESR1 hormone receptor positive
hormone-receptor positive breast cancer
Disease stage
Required: Stage 0, I, II, III
Prior therapy
Must have received: aromatase inhibitor — maintenance
Currently on an aromatase inhibitor
Must have received: antiestrogen (tamoxifen) — maintenance
Currently on ... tamoxifen
Must have received: Selective Estrogen Receptor Modulator — maintenance
Currently on ... Selective Estrogen Receptor Modulators (SERM)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Memorial Sloan Kettering Basking Ridge (Consent Only) · Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (Consent Only) · Middletown, New Jersey
- Memorial Sloan Kettering Bergen (Consent Only) · Montvale, New Jersey
- Memorial Sloan Kettering Cancer Center Suffolk-Commack (Consent Only) · Commack, New York
- Memorial Sloan Kettering Westchester (Consent Only) · Harrison, New York
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify